6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT

    公开(公告)号:US20230416266A1

    公开(公告)日:2023-12-28

    申请号:US18038367

    申请日:2021-11-23

    IPC分类号: C07D491/052 A61P35/00

    CPC分类号: C07D491/052 A61P35/00

    摘要: The disclosure provides compounds of Formula (I)




    or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, CA, R1, R2a, and R2b are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

    Dossier change control management system

    公开(公告)号:US11545270B1

    公开(公告)日:2023-01-03

    申请号:US16748800

    申请日:2020-01-21

    IPC分类号: G16H70/40 G16H20/10

    摘要: A dossier change control management system periodically ingests data regarding a regulated product from multiple data stores. The dossier change control management system updates dossier data describing a dossier history for the regulated product using the received data. The dossier includes multiple documents in a standardized format and is updated based on a data mapping indicating correspondence between fields of the documents and portions of the received data. An out-of-expectation scenario for the dossier is identified based on regulatory requirements and an alert generated. A report with information about the out-of-expectation scenario is provided for display at a client device based on the alert.